Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6489098B1 · kind B1 · utility
7Cited by
1References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 23, 1999 |
| Grant date | Dec 3, 2002 |
| Priority date | — |
| Expiry date | Jun 23, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.